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Abstract
The P2Y14R is a Gi/o-coupled receptor of the P2Y family of purinergic receptors that is activated 
by extracellular UDP and UDP-glucose (UDPG). In an earlier report we described a P2Y14R 
fluorescent probe, MRS4174, based on the potent and selective antagonist PPTN, a naphthoic acid 
derivative. Here, we report the design, preparation, and activity of an agonist-based fluorescent 
probe MRS4183 (11) and a shorter P2Y14R agonist congener, which contain a UDP-glucuronic 
acid pharmacophore and BODIPY fluorophores conjugated through diaminoalkyl linkers. The 
design relied on both docking in a P2Y14R homology model and established structure activity 
relationship (SAR) of nucleotide analogues. 11 retained P2Y14R potency with EC50 value of 0.96 
nM (inhibition of adenylyl cyclase), compared to parent UDPG (EC50 47 nM) and served as a 
tracer for microscopy and flow cytometry, displaying minimal nonspecific binding. Binding 
saturation analysis gave an apparent binding constant for 11 in whole cells of 21.4±1.1 nM, with a 
t1/2 of association at 50 nM 11 of 23.9 min. Known P2Y14R agonists and PPTN inhibited cell 
binding of 11 with the expected rank order of potency. The success in the identification of a new 
P2Y14R fluorescent agonist with low nonspecific binding illustrates the advantages of rational 
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design based on recently determined GPCR X-ray structures. Such conjugates will be useful tools 
in expanding the SAR of this receptor, which still lacks chemical diversity in its collective ligands.
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G protein-coupled receptors (GPCRs) that respond to extracellular uracil and adenine 
nucleotides (P2Y receptors, P2YRs) constitute important and ever-growing targets for 
pharmacological exploration. Eight nucleotide GPCRs are divided into two subfamilies of 
P2YRs, based on sequence and functional similarity: P2Y1R-like, P2Y1,2,4,6,11; and 
P2Y12R-like, P2Y12–14. The P2YRs are broadly distributed among many tissues and are 
expressed in immune cells, intestine, kidney, lung, nervous systems, and others.1
The P2Y14R is involved in inflammation, hypoxia2 and mechanical pain hypersensitivity3, 
and its activation enhances neutrophil chemotaxis4 and promotes the release of mediators 
from mast cells.5 Studies with P2Y14R−/− mice suggested that P2Y14R antagonism might be 
a target for diabetes therapy; another study suggested that P2Y14R activation enhances 
insulin release.6,19 Thus, the P2Y14R is a potential pharmaceutical target for inflammation, 
hypoxia, and endocrine mis-function.
Given the diversity of expression of the P2Y14R and the ubiquitous nature of its endogenous 
activators, i.e. UDP (Chart 1, 1, EC50 160 nM20) and UDP-sugars (2, EC50 261 nM8; 4, 
EC50 370 nM8), the development of ligands selectively targeting this receptor is a 
considerable challenge and an important goal for pharmacological studies and potential 
therapeutic applications. A limited number of chemical classes have been identified as 
ligands and explored for their effects on the P2Y14R: synthetic nucleotide analogues of 1 
and 2, such as 3 (EC50 11 nM20),7, 8 derivatives of 2-naphthoic acid, most notably the potent 
and selective antagonist 4-(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-
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naphthoic acid (PPTN, 5, KB 0.43 nM),9, 10, 11 and substituted pyrido[4,3-d]pyrimidines 
including potent analogue 6 (IC50 10 nM).12
Nucleotide analogues of endogenous P2Y14R agonist 1 would be poor drug candidates due 
to their low bioavailability associated with high charge and their chemical instability due to 
hydrolysis by endonucleotidases. Derivatives of nonnucleotide P2Y14R antagonist 5 also 
suffer from poor drug-like characteristics due to high lipophilicity.9, 13 However, the 
chemical stability, high affinity and selectivity of 5 toward the P2Y14R attracted our 
attention and inspired its use as a template for the development of fluorescent antagonist 
affinity probes.10, 14 We applied virtual docking to design analogues of 5 that retain or 
enhance P2Y14R affinity and tolerate the increase in molecular size and interactions 
associated with fluorophore conjugation. A human (h) P2Y14R homology model was 
constructed based on the recently reported structures of the hP2Y12R.15, 16 This model was 
successfully utilized in predicting a suitable site on 5 for fluorophore conjugation and the 
minimum linker length required to provide adequate spacing between the pharmacophore 
and the fluorophore. The resulting PPTN-Alexa Fluor 488 conjugate (MRS4174, 7) 
displayed sub-nanomolar antagonist affinity at the hP2Y14R and a very low level of 
nonspecific binding. Its binding to the hP2Y14R stably expressed in mammalian cells was 
inhibited by other P2Y14R ligands with the appropriate rank order of potency.
In the present study, we designed with the aid of molecular modeling and synthesized a 
pharmacologically complementary high affinity fluorescent agonist-based probe. The 
suitability of the site of attachment and the dependence of potency on the length of the 
spacer chain were predicted by a structure-based analysis using a homology model of the 
P2Y14R.14,21 Our previous modeling study concluded that the glucose moiety of 4 was the 
most structurally permissive region of this endogenous agonist since it bound in the second 
subpocket of the P2Y14R binding site, which is accessible to the extracellular medium. 
Therefore, two fluorescent derivatives of 4 were designed and prepared (Scheme 1) based on 
predictions from computational modeling of P2Y14R agonist binding.21 The strategy behind 
the selection of these target compounds is described below. The conjugation of a 
fluorophore was accomplished via condensation of commercially available fluorescent 
amines with the carboxylic group of 4.
Based on previous structure activity relationship (SAR) studies of 2, two designs of 
fluorescent affinity probes of varying chain length were compared. The structures of 1 and 
2, now identified as endogenous P2Y14R agonists, have been extensively probed by 
chemical modification with regard to their ability to activate the P2Y14R, as well as P2Y2, 
P2Y4 and P2Y6Rs. 7, 8, 17. The C6 carbon of the hexose moiety of UDPGA 4 was found 
suitable for chain extension with retention of P2Y14R agonist activity. A number of amide 
derivatives at the glucose C6 have been constructed, and most of these derivatives retained 
agonist activity. It was also found that P2Y14R agonist activity was retained with attachment 
of large groups such as unprotected, as well as acetyl- and Boc-protected aminoethylamides, 
and polyamidoamine (PAMAM) dendrimers of generation (G) 3 and 6 attached to the C6 
carbon.17 Moreover, it was found that dendrimer conjugates possessed enhanced potency 
when compared to 4.
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Thus, we chose the structure of 4 as a starting point for designing and building fluorescent 
probes. Our objectives were to facilitate the availability of such affinity probes and to 
validate further the previously constructed computational models. Hence, we chose as our 
primary fluorophore boron-dipyrromethene (BODIPY), which has been used in other 
fluorescent probes of GPCRs.18 Unlike the chemical series of hydrophobic P2Y14R 
antagonist 5, in which a less hydrophobic fluorophore, AlexaFluor 488, in conjugate 7 was 
optimal, the restriction of choosing a hydrophilic fluorophore was relieved due to the 
inherent high polarity and hydrophilicity of 4. Additionally, various BODIPY dyes with 
built-in reactive amine linkers of varying length are readily available commercially. Two 
amide-bound conjugates, 10 and MRS4183 11 (Scheme 1), were docked into a homology 
model of the hP2Y14R to predict their fit prior to synthesis. The target molecules 10 and 11 
contained linkers consisting of 7 and 14 (including benzene ring) atoms, respectively, 
between C6 of hexose and the pyrrole ring of BODIPY.
A homology model of the hP2Y14R was constructed as we reported, based on the high 
resolution X-ray crystallographic structure of the P2Y12R complex with 2-
MeSADP.15, 16, 21 Various known P2Y14R agonists were docked in the orthosteric binding 
site. The attempted docking of the fluorescent agonists 10 and 11 did not provide a 
satisfactory binding pose for conjugate 10, suggesting the inability of the binding pocket to 
accommodate both pharmacophore and fluorophore connected by a short, 7-atom linker 
containing ethylene diamine. However, the hypothetical binding mode of 11 revealed that 
the longer, 14-atom linker containing 1,5-diaminopentane is sufficiently long to connect the 
pharmacophore inside the deep binding site with the fluorophore presented on the 
extracellular side of the receptor (Figure 1). According to the obtained binding mode, the 
nucleobase binds inside the pocket formed by TMs 3–5, including aromatic stacking with 
Y1023.33 (using standard numbering relative to the TMs26) and with carbonyl oxygen atoms 
forming hydrogen bond contacts with side chains of H1845.35 and N1885.39. The ribose 
hydroxyls form contacts with N1564.57 side chain and the backbone carbonyl of C943.25. 
The diphosphate moiety forms salt bridges with positively charged K772.60, K2777.35, and 
R2536.55, and makes polar contacts with Y1023.33 and Q2606.60 side chains. The amide 
functionalities of the linker were found to form hydrogen bond contacts with the side chain 
of K171 (EL2) on the interior of the receptor and the backbone of K270 (EL3) on the 
extracellular part. The linker projects toward the extracellular region via a channel along 
TM3 and through the window formed by EL1 and EL2.
The synthesis of derivatives 10 and 11 was accomplished using standard coupling conditions 
involving the primary amine congeners of the dyes (8 and 9) and the carboxylate group of 
UDP-glucuronic acid 4. In particular, 10 was synthesized initially using 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) as coupling agent and NEt3 as a base, while in the case of 11 
different conditions were tried (Table S1, Supporting Information) to increase the reaction 
yield and simplify the purification process. Indeed, the first attempt (condition A) to 
synthetize 11 resulted in an impure product even after several successive purification 
attempts, due to an impurity co-eluting with the desired product. The higher reactivity of a 
different coupling agent, [[(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-
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ylmethylidene]-dimethylazanium hexafluorophosphate (COMU, conditions B and C), 
compared to HATU led to the formation of numerous side products during the reaction that 
complicated the purification process (2 or 3 purifications) without leading to a significant 
detectable amount of title compound. Nevertheless, the best performing procedure 
(condition D), using excess 4 (1.5 equivalents), COMU (1.5 equivalents) as coupling agent 
and DIPEA (2 equivalents) as base, provided the desired, pure product after one purification 
step using a C18 HPLC column, however, in a very low yield (0.3%). 11 was found to have 
excitation and emission maxima at 590 and 616 nm, respectively (Figure S2, Supporting 
information).
Both 10 and 11 were evaluated functionally in Chinese hamster ovary (CHO) cells stably 
expressing the Gi-coupled human P2Y14R (CHO- P2Y14R) for capacity to inhibit forskolin-
stimulated 3′,5′-cyclic adenosine monophosphate (cAMP) accumulation (Figure 2).10 
UDPGABODIPY conjugate 11 retained its agonist activity with a nanomolar EC50 value. 
The EC50 value of 0.96 nM for inhibition of cAMP production in hP2Y14R-expressing CHO 
cells, compared to 47 nM for 4, constitutes a 50-fold potency enhancement in the fluorescent 
conjugate. Thus, 11 improved upon the potency of parent UDP-sugars despite the presence 
of a large fluorophore attached to its hexose C6 position. Accordingly, 11 demonstrated 
strong specific binding to P2Y14R-CHO cells in flow cytometry (FCM) (Figures 3A, B & 
C). The level of nonspecific binding determined by coincubating with up to 200 nM 5 was 
very low. We also quantified saturation of binding of 11 to CHO cells expressing P2Y14R 
using FCM. Increasing concentrations of 11 from 1 nM to 500 nM were used to calculate the 
total binding, and nonspecific binding was determined in the presence of 20 μM 5. From the 
saturation curve, an apparent binding constant (Kd app) was determined to be 21.4±1.1 nM 
(Figure 4A). The kinetics of 11 binding in CHO cells expressing P2Y14R was studied using 
FCM, and the t1/2 of binding of 50 nM 11 was 23.9 min (Figure 4B).
Competition for fluorescent binding with known P2Y14R ligands and P2Y6R ligands was 
also performed. These two types of ligands were compared because both receptors are 
activated by UDP, and no other P2YRs respond to UDP. To determine the Ki values of 
known ligands, we used 11 as a tracer, at a concentration of 50 nM. Competitive binding 
results with known nucleotide agonists and nonnucleotide antagonist 5 shown in Table 1 
roughly followed the expected rank order of P2Y14R potency (5 >> 3 > 1 > 2 > 4). The 
P2Y6R agonist MRS2957 12, a dinucleoside triphosphate, also inhibited binding of 11, but 
with a Ki value of 5.18 μM, which is about 500-fold higher than its EC50 value (12 nM) for 
activation of the P2Y6R.24 The nonnucleotide antagonist of P2Y6R, MRS2578 13,25 did not 
show any significant binding to P2Y14R at 10 μM, thus confirming its P2Y6R selectivity. As 
predicted by computational modeling, conjugate 10 was much weaker than 11, with an EC50 
of 91 nM for inhibition of cAMP accumulation in P2Y14R-CHO cells. However, over a 
range of concentrations (0.05 −1 μM) it did not demonstrate significant fluorescence binding 
in comparison to nonspecific binding in FCM experiments (data not shown).
Confocal fluorescence microscopy indicated specific labeling of P2Y14R-CHO cells by 11 
(Figure 5). The fluorescent labeling was inhibited in the presence of competing antagonist 5 
and was also absent in control CHO cells lacking P2Y14R expression (not shown). The label 
appears irregularly distributed on the surface of the cells and partially internalized, 
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consistent with 11 being an agonist of the P2Y14R. Similarly, the internalization of 
fluorescent agonists of other P2YRs and GPCRs was reported.22,23
In conclusion, we applied computational tools and known P2Y14R agonist SAR toward 
design of a new agonist fluorescent probe. An insensitive site on the glucose moiety of 4 
was covalently derivatized, and two linkers of different length were tested both 
computationally and experimentally. The demonstrated predictive strength of the utilized 
approach highlights the validity and usefulness of this particular P2Y14R homology model 
and the strategy at large when applied toward probe design. Additionally, the lack of 
fluorescent binding of the analogue 10 with a shorter linker and the strong binding of 11 
provide an additional estimate of the shape, size and depth of the orthosteric ligand binding 
pocket of the P2Y14R. Thus, we have used insights from P2YR structures and modeling to 
identify 11 as a useful agonist fluorescent probe of the P2Y14R, which has high affinity and 
low nonspecific binding. Its binding properties and inhibition by known P2YR ligands could 
readily be determined using FCM. Our previous efforts to characterize this receptor included 
the design and preparation of a fluorescent probe based on the potent and selective 
antagonist 5. In order to further the study the role and distribution of this receptor, we 
introduce here a useful fluorescent probe that is pharmacologically complementary to our 
reported nonnucleotide fluorescent antagonist 7. The utility of this probe to detect P2Y14R 
using fluorescence microscopy was also demonstrated. Further studies with regard to 
fluorescence binding of both agonist and antagonist probes and receptor pharmacology as 
well as their suitability for ligand affinity screening are currently underway.
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MESF molecules of equivalent soluble fluorochrome
MRS2578 N,N”-1,4-butanediylbis[N’-(3-isothiocyanatophenyl)]thiourea]
MRS2957 P1-(uridine 5′-)-P3-( N4-methoxycytidine 5′-)triphosphate
PPTN 4-(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic 
acid
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Hypothetical binding mode of 11 in a hP2Y14R homology model based on the structure of 
the nucleotide-bound hP2Y12R.14,21 12 The BODIPY fluorophore is predicted to interact 
with residues of the ELs, including K270. Other residues shown correspond to TMs: 2 
(K772.60, D812.64); 3 (Y1023.33); 5 (H1845.35, N1885.39); 6 (R2536.55, Q2606.62); 7 
(K2777.35).
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Concentration-response curves for endogenous agonist 2 (blue), short-chain conjugate 10 
(red) and long-chain conjugate 11 (black) for inhibition of forskolin-stimulated cAMP 
formation in P2Y14R-expressing CHO cells, as described.14 Incubations were at 37 °C for 
15 min and were terminated by aspiration of medium and addition of 500 μL of ice-cold 5% 
trichloroacetic acid. All assays with 6, 22, and 30 also contained 30 μM forskolin and 200 
μM IBMX, 3-isobutyl-1-methylxanthine, a phosphodiesterase inhibitor. Data points for 
IBMX alone (indicated by IBMX in the legend) and forskolin + IBMX (indicated by 
forskolin in the legend) also are shown.
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(A) Inhibition of binding of 11 in P2Y14R-CHO cells by antagonist PPTN 5 and agonists 
UDP 1 and UDPG 2 (10 μM), analyzed by flow cytometry. Incubation of cells for 30 min 
with antagonist 5 or agonist 1 or 2 (all at 10 μM) followed by incubation with 11 (50 nM) 
for 30 min was performed. (B) Dependence of fluorescent labeling of P2Y14R-CHO cells on 
the concentration of 11, analyzed by flow cytometry. Incubation of cells with a variable 
concentration of 11 (1 nM – 500 nM) was performed following 60 min of incubation in the 
absence or presence of PPTN 5 (200 nM). Nearly complete inhibition of binding was 
observed up to 100 nM 11. (C) Fluorescence ligand binding experiments using FCM in 
P2Y14R-CHO cells with 11 (50 nM) after 30 min pre-incubation at 37 °C with known 
P2Y14R agonists 1 and 2 or P2Y14R antagonist 5 (each 10 μM). Each column shows the 
fluorescent intensity of each compound using 11 normalized to 100% for each time point 
and after correcting the mean fluorescence intensity values for auto fluorescence. Results are 
expressed as mean±S.E (n=3).
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(A) Saturation binding assays (B) binding kinetics with tracer 11 using FCM following 
incubation for 30 min with CHO cells expressing the hP2Y14R. Mean fluorescent Intensity 
values from FCM were converted to MESF values (Figure S6) using Quickcal program v. 
2.3 (Bangs Laboratories Inc., Fishers, IN). Nonspecific binding was measured in the 
presence of 11 and 20 μM 5. Results are expressed as mean±S.E (n=3). In (A), the Kd value 
is 26.1±3.6 nM, Bmax = 44,400 MESF (n=3). In (B), 100% corresponds to a MESF value of 
26,900.
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Fluorescence confocal microscopy. Fluorescent labeling of P2Y14R-CHO cells by 11, 
analyzed by confocal fluorescence microscopy. Incubation of cells with a fixed 
concentration of 11 (200 nM) was performed following 30 min (A, B) or 120 min (C, D) of 
incubation in the absence (A, C) or presence (B, D) of antagonist 5 (10 μM). The complete 
inhibition of binding was observed in the presence of the antagonist. Scale of 60 μm is 
shown in D. The excitation laser used had a peak at 555 nm and was equipped with a 561 
nm filter. Emitted fluorescence was measured without a filter.
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Representative P2Y14R agonists 1–4, antagonists 5, 6 and fluorescent antagonist MRS 4174 
7.
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Synthesis of fluorescent conjugates of 4. aReagents and conditions: i: HATU, Et3N, DMF, 
23 °C, 2% yield; ii: COMU (1.5 eq.), DIPEA (2 eq.), DMF, 0 °C, 0.3% yield.
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Table 1
Inhibition of P2Y14R binding in whole cells by known ligands of P2Y14R and P2Y6R using 11 as a FCM 
tracer. Results are expressed as mean±S.E (n=3).a
Compound hP2Y14R cAMP assay
(EC50 or IC50b, μM)
FCM binding at hP2Y14R
(Ki, μM)
P2Y14 ligands
1 UDP 0.160 0.63±0.03
2 UDP-glucose 0.261 2.23±0.2
3 MRS2690 0.011 0.34±0.04
4 UDP-glucuronic acid 0.370 5.3±0.4
5 PPTN 0.00043 0.0019±0.0001
P2Y6 ligands
12 MRS2957c ND 5.18±0.20
13 MRS2578c ND No inhibition at 10 μM
a
FCM binding was measured in CHO cells expressing the hP2Y14R using a fixed concentration (50 nM) of 11, following an incubation of 30 min. 
Values in the cAMP assay were from published reports.10,20,21,24 ND, not determined.
b
IC50 values for P2YR antagonists 5 and 13.
c
Structures:
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